New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma

Lorente, Leonardo

doi:10.3748/wjg.v24.i37.4230

Cited by 19 publications

(16 citation statements)

References 159 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 VEGF or MMP-9 plays important roles in tumor angiogenesis and has clinical significance in the diagnosis, treatment, and prognosis of various cancers, including HCC. [23][24][25][26] EGFR inhibitor can decrease the tumorigenesis of LC cells by regulating the ERK-EGF/MMP-9 signaling pathway. 27 Thus, EGFR may have important correlation with VEGF and MMP-9 in tumor progression.…”

Section: Discussionmentioning

confidence: 99%

<p>Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization</p>

Cao

Zhu

Yin

et al. 2020

OTT

View full text Add to dashboard Cite

The aim of this study was to estimate the relevance of the epidermal growth factor receptor (EGFR) between serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9) in primary hepatocellular carcinoma (HCC) patients with transarterial chemoembolization (TACE). Methods: The pre-treatment and post-treatment concentrations of the serum VEGF and MMP-9 were detected with Luminex assay in 80 EGFR-negative patients and 59 EGFRpositive patients who received TACE therapy with different chemotherapeutic drugs. Results: The serum concentration of MMP-9 in the EGFR-positive patients with primary HCC was significantly higher than that in the EGFR-negative patients (P < 0.05). In EGFRpositive patients with primary HCC, differences in stage, metastasis, and differentiation were significant (P < 0.05). Serum VEGF level significantly decreased at the second course of treatment in the EGFR-negative patients from the P group (P < 0.05), while serum MMP-9 level significantly decreased at the second course of treatment in the EGFR-negative patients from the E group (P < 0.05). Serum VEGF level in the EGFR-positive patients among three groups slightly decreased at the first, second and third courses of treatments; however, the differences were not significant (P > 0.05). Serum MMP-9 level in the EGFR-positive patients among three groups showed mild decrease at the first and second courses of treatments; however, the decreases at the third course of treatment were significant (P < 0.05). Conclusion: Serum VEGF and MMP-9 are potential biomarkers for the treatment monitoring of EGFR-positive and-negative patients after TACE therapy with different chemotherapeutic drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization</p>

Cao

Zhu

Yin

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…The most examined biomarker is the serum AFP level. In addition, an association has been found between increased HCC recurrence and high serum levels of Des-gamma -carboxy prothorombin, E-cadherin, beta-catenin and high HCC expression of GPC-3 but additional research is necessary to establish the prognostic role these biomarkers [45].…”

Section: Discussionmentioning

confidence: 99%

Are the criteria always right? Assessment of hepatocellular carcinoma cases in living donor liver transplantation at a high-volume center

et al. 2021

View full text Add to dashboard Cite

Background/Aim: With the increased experience in living donor liver transplantation (LDLT), it has been adopted for the treatment of hepatocellular carcinoma (HCC), with emerging discussions of criteria beyond tumor size and number. In contrast to deceased donor liver transplantation (DDLT), recipient selection for LDLT is not limited by organ allocation systems. We discuss here in the assessment, criteria and experience with LT in HCC cases at a high-volume LDLT center. Material and Methods: Between August 2006 and December 2017, 191 adult LT HCC recipients with at least one-year follow-up were retrospectively analyzed. Results: In 191 patients, one-, three-and five-year survival rates were 87.2%, 81.6%, and 76.2%. respectively, including early postoperative mortality. In 174 patients with long-term follow-up, one-, three-and five-year disease-free survival rates were 91.6%, 87.7% and 84.4%, respectively. When multivariate analysis was utilized tumor differentiation was the only factor which statistically affected survival (p=0.025). Conclusions: LDLT allows us to push the limits forward and the question "Are the criteria always right?" is always on the table. We can conclude that, with the advantage of LDLT, every HCC patient deserves a case-by-case basis discussion for LT under scientific literature support. In borderline cases, tumor biopsy might help determine the decision for LT.

show abstract

“…Multiple groups have recently published research concerning SP and its analogues or derivatives as agonistic or antagonistic peptide NK1R ligands [7,8,19,21,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65]. New unnatural peptides are designed in order to improve their biological properties (e.g., half-life, receptor affinity and lipophilicity).…”

Section: Nk1r Ligands In Classical Medicinementioning

confidence: 99%

The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy

2019

View full text Add to dashboard Cite

To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy.

show abstract

New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma

Cited by 19 publications

References 159 publications

<p>Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization</p>

<p>Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization</p>

Are the criteria always right? Assessment of hepatocellular carcinoma cases in living donor liver transplantation at a high-volume center

The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy

Contact Info

Product

Resources

About